微流控分选与密度梯度离心联合上游法在拆分精液样本中选择DNA损伤更低的精子用于临床
本研究为盲法对照实验室研究,对70例不育男性常规精液分析后弃用的样本进行拆分,比较微流控芯片分选与密度梯度离心联合上游法对精子DNA碎片指数的影响。结果显示微流控芯片处理后的DFI中位数为0%,显著低于密度梯度离心法的6%和未处理样本的21%,且在高DFI四分位样本中同样显著降低。
要点
- 微流控分选可从未处理精液中选出高活力、DNA碎片几乎检测不到的精子。
- 芯片组DFI中位数0%,显著低于密度梯度离心组的6%和未处理组的21%。
- 高DFI四分位样本中,芯片组DFI中位数0%亦显著低于密度梯度离心组的15%。
核心结论
- 微流控分选未处理精液可选择临床可用、高活力且DNA碎片几乎检测不到的精子。
- 标准密度梯度离心联合上游法在不育人群中未增加DNA碎片。
研究设计与样本
- 盲法对照实验室研究,纳入不育男性常规精液分析后弃用样本70例,样本拆分后分别处理。
主要发现
- 未处理样本DFI中位数21%(IQR 14-30)。
- 芯片组DFI中位数0%(IQR 0-2.4),密度梯度离心组DFI中位数6%(IQR 2-11),芯片组较密度梯度离心组显著降低(P=0.0029),较未处理样本亦显著降低(P<0.0001)。
- 最高DFI四分位(DFI范围31-40%)样本中,密度梯度离心后DFI中位数15%(IQR 11-19%),芯片处理后DFI中位数0%(IQR 0-1.9%),芯片组显著降低(P=0.02)。
关键数值与推荐
- DFI按每张玻片最多300个细胞中DNA碎片细胞数除以计数细胞数计算。
- 精子浓度、前向活力和前向运动分级通过显微镜检查评估。
- DNA碎片通过精子染色质扩散实验评估。
临床怎么用
- 作者提出该微流控技术提供无流式分选精子方法,无需周边设备或过滤步骤,并减少手工操作时间。
- 作者指出高DFI与IVF/ICSI不良结局相关,但降低DFI改善临床结局的数据有限,本研究使用弃用非临床样本,无法获得临床结局数据。
局限性
- 高DFI与IVF/ICSI不良结局相关,但降低DFI改善临床结局的数据有限。
- 本研究使用弃用的非临床样本,无法获得临床结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does microfluidic sorting improve the selection of sperm with lower DNA fragmentation over standard density-gradient centrifugation? SUMMARY ANSWER: Microfluidic sorting of unprocessed semen allows for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation. WHAT IS KNOWN ALREADY: Microfluidic devices have been explored to sort motile and morphologically normal sperm from a raw sample without centrifugation; however, it is uncertain whether DNA damage is reduced in this process. STUDY DESIGN, SIZE, DURATION: This is a blinded, controlled laboratory study of differences in standard semen analysis parameters and the DNA fragmentation index (DFI) in split samples from infertile men (n = 70) that were discarded after routine semen analysis at an academic medical center. PARTICIPANTS/MATERIALS, SETTING, METHODS: Sperm concentration, progressive motility and forward progression were assessed by microscopic examination. For each sample, the unprocessed semen was tested for DNA fragmentation and split for processing by density-gradient centrifugation with swim-up or sorting by a microfluidic chip. DNA fragmentation was assessed in unprocessed and processed samples by sperm chromatin dispersion assay. The DFI was calculated, from up to 300 cells per slide, as the number of cells with fragmented DNA divided by the number of cells counted per slide. MAIN RESULTS AND THE ROLE OF CHANCE: The median DFI in unprocessed samples was 21% (interquartile range (IQR): 14-30). In paired analyses of all samples, those processed by the microfluidic chip demonstrated significantly decreased DFI compared to those processed by density-gradient centrifugation (P = 0.0029) and unprocessed samples (P < 0.0001). The median DFI for chip specimens was 0% (IQR: 0-2.4) while those processed by density-gradient centrifugation had a median DFI of 6% (IQR: 2-11). Unprocessed samples in the highest DFI quartile (DFI range: 31-40%) had a median DFI of 15% (IQR: 11-19%) after density-gradient centrifugation and DFI of 0% (IQR: 0-1.9%) after processing with the microfluidic chip (P = 0.02). LIMITATIONS, REASONS FOR CAUTION: While a high DFI has been associated with poor outcomes with IVF/ICSI, there are limited data illustrating improvements in clinical outcomes with a reduction in DFI. As this study utilized discarded, non-clinical samples, clinical outcomes data are not available. WIDER IMPLICATIONS OF THE FINDINGS: While microfluidic sorting of unprocessed semen allowed for the selection of clinically usable, highly motile sperm with nearly undetectable levels of DNA fragmentation, standard processing by density-gradient centrifugation with swim-up did not increase DNA fragmentation in an infertile population. The proposed microfluidic technology offers a flow-free approach to sort sperm, requiring no peripheral equipment or filtration step, while minimizing hands-on time. STUDY FUNDING/COMPETING INTEREST(S): No external funding to declare. Utkan Demirci, PhD is the Co-founder and Scientific Advisor for DxNow Inc., LevitasBio Inc. and Koek Biotech. Mitchell Rosen, MD is a member of the Clinical Advisory Board for DxNow Inc.
引用
- Quinn MM, Jalalian L, Ribeiro S, et al. Microfluidic sorting selects sperm for clinical use with reduced DNA damage compared to density gradient centrifugation with swim-up in split semen samples. Hum Reprod. 2018. PMID: 30007319. doi:10.1093/humrep/dey239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。